Potent 19-norvitamin D analogs for prostate and liver cancer therapy

Atsushi Kittaka, Akihiro Yoshida, Kun Chun Chiang, Masashi Takano, Daisuke Sawada, Toshiyuki Sakaki, Tai C. Chen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The active form of vitamin D3, 1α,25(OH)2D 3 or calcitriol, is known to inhibit the proliferation and invasiveness of many types of cancer cells, including prostate and liver cancer cells. These findings support the use of 1α,25(OH)2D 3 for prostate and liver cancer therapy. However, 1α,25(OH)2D3 can cause hypercalcemia, thus, analogs of 1α,25(OH)2D3 that are less calcemic but exhibit potent antiproliferative activity would be attractive as therapeutic agents. We have developed 2α-functional group substituted 19-norvitamin D3 analogs with and without 14-epimerization. Among them, 2α- and 2β-(3-hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (MART-10 and -11, respectively) and 14-epi-2α- and 14-epi-2β-(3- hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (14-epi-MART-10 and 14-epi-MART-11, respectively) were found to be the most promising. In this review, we discuss the synthesis of this unique class of vitamin D analogs, the molecular mechanism of anticancer actions of vitamin D, and the biological evaluation of these analogs for potential application to the prevention and treatment of prostate and liver cancer.

Original languageEnglish
Pages (from-to)2049-2065
Number of pages17
JournalFuture Medicinal Chemistry
Volume4
Issue number16
DOIs
Publication statusPublished - Oct 2012
Externally publishedYes

Fingerprint

Liver Neoplasms
Prostatic Neoplasms
Vitamin D
Calcitriol
Cholecalciferol
Hypercalcemia
Therapeutics
Neoplasms
1,25-dihydroxy-19-norvitamin D3
19-nor-2-(3-hydroxypropyl)-1,25-dihydroxyvitamin D3

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Kittaka, A., Yoshida, A., Chiang, K. C., Takano, M., Sawada, D., Sakaki, T., & Chen, T. C. (2012). Potent 19-norvitamin D analogs for prostate and liver cancer therapy. Future Medicinal Chemistry, 4(16), 2049-2065. https://doi.org/10.4155/fmc.12.130

Potent 19-norvitamin D analogs for prostate and liver cancer therapy. / Kittaka, Atsushi; Yoshida, Akihiro; Chiang, Kun Chun; Takano, Masashi; Sawada, Daisuke; Sakaki, Toshiyuki; Chen, Tai C.

In: Future Medicinal Chemistry, Vol. 4, No. 16, 10.2012, p. 2049-2065.

Research output: Contribution to journalArticle

Kittaka, A, Yoshida, A, Chiang, KC, Takano, M, Sawada, D, Sakaki, T & Chen, TC 2012, 'Potent 19-norvitamin D analogs for prostate and liver cancer therapy', Future Medicinal Chemistry, vol. 4, no. 16, pp. 2049-2065. https://doi.org/10.4155/fmc.12.130
Kittaka, Atsushi ; Yoshida, Akihiro ; Chiang, Kun Chun ; Takano, Masashi ; Sawada, Daisuke ; Sakaki, Toshiyuki ; Chen, Tai C. / Potent 19-norvitamin D analogs for prostate and liver cancer therapy. In: Future Medicinal Chemistry. 2012 ; Vol. 4, No. 16. pp. 2049-2065.
@article{c1d3b69a51b94f909518c7de2b8ab1d0,
title = "Potent 19-norvitamin D analogs for prostate and liver cancer therapy",
abstract = "The active form of vitamin D3, 1α,25(OH)2D 3 or calcitriol, is known to inhibit the proliferation and invasiveness of many types of cancer cells, including prostate and liver cancer cells. These findings support the use of 1α,25(OH)2D 3 for prostate and liver cancer therapy. However, 1α,25(OH)2D3 can cause hypercalcemia, thus, analogs of 1α,25(OH)2D3 that are less calcemic but exhibit potent antiproliferative activity would be attractive as therapeutic agents. We have developed 2α-functional group substituted 19-norvitamin D3 analogs with and without 14-epimerization. Among them, 2α- and 2β-(3-hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (MART-10 and -11, respectively) and 14-epi-2α- and 14-epi-2β-(3- hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (14-epi-MART-10 and 14-epi-MART-11, respectively) were found to be the most promising. In this review, we discuss the synthesis of this unique class of vitamin D analogs, the molecular mechanism of anticancer actions of vitamin D, and the biological evaluation of these analogs for potential application to the prevention and treatment of prostate and liver cancer.",
author = "Atsushi Kittaka and Akihiro Yoshida and Chiang, {Kun Chun} and Masashi Takano and Daisuke Sawada and Toshiyuki Sakaki and Chen, {Tai C.}",
year = "2012",
month = "10",
doi = "10.4155/fmc.12.130",
language = "English",
volume = "4",
pages = "2049--2065",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "16",

}

TY - JOUR

T1 - Potent 19-norvitamin D analogs for prostate and liver cancer therapy

AU - Kittaka, Atsushi

AU - Yoshida, Akihiro

AU - Chiang, Kun Chun

AU - Takano, Masashi

AU - Sawada, Daisuke

AU - Sakaki, Toshiyuki

AU - Chen, Tai C.

PY - 2012/10

Y1 - 2012/10

N2 - The active form of vitamin D3, 1α,25(OH)2D 3 or calcitriol, is known to inhibit the proliferation and invasiveness of many types of cancer cells, including prostate and liver cancer cells. These findings support the use of 1α,25(OH)2D 3 for prostate and liver cancer therapy. However, 1α,25(OH)2D3 can cause hypercalcemia, thus, analogs of 1α,25(OH)2D3 that are less calcemic but exhibit potent antiproliferative activity would be attractive as therapeutic agents. We have developed 2α-functional group substituted 19-norvitamin D3 analogs with and without 14-epimerization. Among them, 2α- and 2β-(3-hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (MART-10 and -11, respectively) and 14-epi-2α- and 14-epi-2β-(3- hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (14-epi-MART-10 and 14-epi-MART-11, respectively) were found to be the most promising. In this review, we discuss the synthesis of this unique class of vitamin D analogs, the molecular mechanism of anticancer actions of vitamin D, and the biological evaluation of these analogs for potential application to the prevention and treatment of prostate and liver cancer.

AB - The active form of vitamin D3, 1α,25(OH)2D 3 or calcitriol, is known to inhibit the proliferation and invasiveness of many types of cancer cells, including prostate and liver cancer cells. These findings support the use of 1α,25(OH)2D 3 for prostate and liver cancer therapy. However, 1α,25(OH)2D3 can cause hypercalcemia, thus, analogs of 1α,25(OH)2D3 that are less calcemic but exhibit potent antiproliferative activity would be attractive as therapeutic agents. We have developed 2α-functional group substituted 19-norvitamin D3 analogs with and without 14-epimerization. Among them, 2α- and 2β-(3-hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (MART-10 and -11, respectively) and 14-epi-2α- and 14-epi-2β-(3- hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (14-epi-MART-10 and 14-epi-MART-11, respectively) were found to be the most promising. In this review, we discuss the synthesis of this unique class of vitamin D analogs, the molecular mechanism of anticancer actions of vitamin D, and the biological evaluation of these analogs for potential application to the prevention and treatment of prostate and liver cancer.

UR - http://www.scopus.com/inward/record.url?scp=84869444574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869444574&partnerID=8YFLogxK

U2 - 10.4155/fmc.12.130

DO - 10.4155/fmc.12.130

M3 - Article

C2 - 23157238

AN - SCOPUS:84869444574

VL - 4

SP - 2049

EP - 2065

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 16

ER -